BeNeLuxBelgiumNetherlandsLuxembourg

Galapagos discontinues partnered RA programme

18.04.2011

Mechelen – Belgian Galapagos NV has terminated a Phase 2 study for
GLP0259 in rheumatoid arthritis after an interim analysis showed the drug was not efficient. The failure affects Galapagos’ research agreement with Janssen Pharmaceutica for arthritis, under which the J&J subsidiary has the option to exclusively license four small molecules from in RA from Galapagos for 60 million euros each, upon delivery of Phase IIa results and further potential EUR776 million in case of market launch. Onno van de Stolpe, CEO of Galapagos said: "Galapagos remains on-track to deliver the remainder of its operational objectives in 2011 as well as meet full year financial guidance of at least EUR150 million in revenues, profitability and positive cash flow in 2011."

BeNeLuxBelgiumNetherlandsLuxembourg

07.09.2011

Diepenbeek - Amakem has received €18m to take a glaucoma drug candidate through Phase II trials. The Belgium-based developer lead candidate will use the money to advance its lead candidate AMA0076 to the clinical proof of...

BeNeLuxBelgiumNetherlandsLuxembourg

01.09.2011

New York - US-American investment firm OrbiMed announced the closing of a new fund for life science companies in the health sector. The fund acquires healthcare royalty streams and provides structured debt capital to healthcare...

BeNeLuxBelgiumNetherlandsLuxembourg

31.08.2011

Leiden/Stockholm – Dutch Pharming Group NV and Swedish specialist for rare diseases Orphan Biovitrum AB, have launched their recombinant C1 inhibitor Ruconest® in the Netherlands. The launch of the treatment for patients...

BeNeLuxBelgiumNetherlandsLuxembourg

22.08.2011

Leuven – ThromboGenics NV presented promising results of its Ocriplasmin Phase III clinical program at the Annual Meeting of the American Society of Retina Specialists (ASRS). „We remain on track to make regulatory filings for...

BeNeLuxBelgiumNetherlandsLuxembourg

18.08.2011

Liège – A Belgian research team from the University of Liège’s GIGA-Research centre has discovered an unexpected mode of action for the vaccine adjuvant alum. The team discovered that when a vaccine containing alum is injected...

BeNeLuxBelgiumNetherlandsLuxembourg

16.08.2011

Amsterdam – Dutch molecular diagnostics specialist Agendia B.V. postponed its initial public offering in June because of volatile market conditions, revealing that the financing environment for bio­tech firms remains tough....

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2011

Dutch gene therapy specialist Amsterdam Molecular Therapeutics BV (AMT) has filed a re-examination request for its lead product Glybera. At the end of June, EMA's CHMP recommended against approval of the product to treat...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Ghent – The Flanders Institute for Biotechnology VIB will receive EUR3m from the European Commission for the recruitment and training of promising international scientists in the life sciences. This will allow VIB to further...

Displaying results 31 to 40 out of 304

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/3/article/galapagos-discontinues-partnered-ra-programme.html

Image Gallery

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR53.3%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-44.9%
  • PROTHENA PLC (IE)28.07 USD-40.8%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 19.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper